PTGS2 - Prostaglandin-Endoperoxide Synthase 2

Migration, Crosslink

📖

PTGS2 - Prostaglandin-Endoperoxide Synthase 2

active

wiki page Created: 2026-04-02T07:19:17 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ptgs2

📖 Wiki Page

gene2509 wordssynced 2026-04-02

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PTGS2 - Prostaglandin-Endoperoxide Synthase 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PTGS2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Prostaglandin-Endoperoxide Synthase 2 (Cyclooxygenase-2)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>1q31.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5743</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>600262</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000073756</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P35354</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>prostaglandin synthase family</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>Cyclooxygenase-2 (COX-2), 71 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Constitutive</td>
</tr>
<tr>
<td class="label">Active site size</td>
<td>Smaller</td>
</tr>
<tr>
<td class="label">Substrate diversity</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Physiological roles</td>
<td>Protective (GI, platelets)</td>
</tr>
<tr>
<td class="label">Tissue distribution</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">Response to NSAIDs</td>
<td>Sensitive</td>
</tr>
<tr>
<td

...

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PTGS2 - Prostaglandin-Endoperoxide Synthase 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PTGS2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Prostaglandin-Endoperoxide Synthase 2 (Cyclooxygenase-2)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>1q31.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5743</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>600262</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000073756</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P35354</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>prostaglandin synthase family</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>Cyclooxygenase-2 (COX-2), 71 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Constitutive</td>
</tr>
<tr>
<td class="label">Active site size</td>
<td>Smaller</td>
</tr>
<tr>
<td class="label">Substrate diversity</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Physiological roles</td>
<td>Protective (GI, platelets)</td>
</tr>
<tr>
<td class="label">Tissue distribution</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">Response to NSAIDs</td>
<td>Sensitive</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Celecoxib</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">Rofecoxib</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Etoricoxib</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Aprinocarsen</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">SC-236</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1971</td>
<td>Discovery of COX enzyme</td>
</tr>
<tr>
<td class="label">1991</td>
<td>COX-2 cloning and characterization</td>
</tr>
<tr>
<td class="label">1998</td>
<td>First selective COX-2 inhibitor approved</td>
</tr>
<tr>
<td class="label">2000</td>
<td>COX-2 in AD brain documented</td>
</tr>
<tr>
<td class="label">2004</td>
<td>COX-2 in PD model</td>
</tr>
<tr>
<td class="label">2005</td>
<td>Vioxx withdrawn (cardiovascular risk)</td>
</tr>
<tr>
<td class="label">2011</td>
<td>COX-2 genetic variants characterized</td>
</tr>
<tr>
<td class="label">2020</td>
<td>Novel therapeutic strategies review</td>
</tr>
<tr>
<td class="label">2024</td>
<td>COX-2 and tau pathology</td>
</tr>
<tr>
<td class="label">Expression pattern</td>
<td>Constitutive</td>
</tr>
<tr>
<td class="label">Physiological roles</td>
<td>Homeostasis</td>
</tr>
<tr>
<td class="label">Tissue distribution</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">Promoter elements</td>
<td>TATA box</td>
</tr>
<tr>
<td class="label">Response to NSAIDs</td>
<td>Constitutively sensitive</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">442 edges</a></td>
</tr>
</table>

Introduction

The PTGS2 gene (Prostaglandin-Endoperoxide Synthase 2), more commonly known by its protein product cyclooxygenase-2 (COX-2), encodes a key enzyme in the prostaglandin biosynthesis pathway that plays a pivotal role in neuroinflammation and neurodegenerative disease pathogenesis. COX-2 is an inducible enzyme that converts arachidonic acid to prostaglandin H2 (PGH2), the precursor for prostaglandins, thromboxanes, and prostacyclins. Unlike its constitutive counterpart COX-1 (PTGS1), COX-2 is primarily induced by inflammatory stimuli, making it a major therapeutic target for anti-inflammatory drugs and a critical mediator of neuroinflammation in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. [@smith2000]

The PTGS2 gene has been extensively studied in the context of neurodegeneration, with elevated COX-2 expression documented in affected brain regions of patients with AD, PD, and ALS. This overexpression contributes to chronic neuroinflammation through the production of pro-inflammatory prostaglandins, particularly prostaglandin E2 (PGE2), which drives microglial activation, cytokine release, and neuronal dysfunction. [@minghetti2000]

Gene Overview

Gene Structure and Regulation

Genomic Architecture

The PTGS2 gene spans approximately 8.3 kilobases on chromosome 1q31.1 and consists of 10 exons. The gene structure is highly conserved across mammals, reflecting its essential physiological functions. The promoter region of PTGS2 is notably rich in transcription factor binding sites, enabling rapid induction in response to inflammatory signals. [@smith2000]

Transcriptional Regulation

PTGS2 expression is tightly controlled at the transcriptional level through multiple signaling pathways:

NF-κB pathway: The primary inducer of COX-2 expression. Pro-inflammatory cytokines (TNF-α, IL-1β), LPS, and cellular stress activate IKK kinase, leading to IκB degradation and nuclear translocation of the p65/p50 NF-κB heterodimer. Multiple NF-κB binding sites exist in the PTGS2 promoter. [@wang2020]

MAPK signaling: p38 MAPK, JNK, and ERK pathways contribute to COX-2 induction through activation of transcription factors including AP-1 and C/EBP.

cAMP/PKA pathway: Elevated cAMP can induce COX-2 expression through CRE (cAMP response element) binding.

PPARγ activation: Peroxisome proliferator-activated receptor gamma (PPARγ) can repress COX-2 expression, providing a potential therapeutic intervention point.

Epigenetic regulation: DNA methylation and histone modifications influence PTGS2 expression, with hypomethylation associated with increased expression in diseased tissue.

Post-Transcriptional Regulation

PTGS2 mRNA stability is regulated by AU-rich elements (AREs) in the 3' untranslated region. RNA-binding proteins such as HuR can stabilize the mRNA, while microRNAs (miR-146a, miR-101) can repress translation.

Protein Structure and Function

Structural Architecture

COX-2 is a homodimeric enzyme with two functional domains:

N-terminal peroxidase domain (residues 1-72): Contains the heme prosthetic group (Fe-protoporphyrin IX) and is responsible for reducing peroxide tone, which is essential for cyclooxygenase activity.

C-terminal cyclooxygenase domain (residues 83-604): Catalyzes the conversion of arachidonic acid to PGH2. This domain contains the active site and substrate channel.

Key Structural Features

Active site: Notably larger than COX-1 (15% volume difference), allowing substrate diversity including arachidonic acid and docosahexaenoic acid (DHA)
Glycosylation sites: Three N-linked glycosylation sites (Asn53, Asn144, ns410) for membrane association
Peroxidase active site: Contains heme (Fe-protoporphyrin IX) as a cofactor
Substrate channel: Arachidonic acid access controlled by gatekeeper residues (Arg-120, Val-523)
Aspirin acetylation site: Ser-530 is acetylated by aspirin, irreversibly inhibiting the enzyme

Catalytic Mechanism

The COX-2 catalytic cycle involves:

Heme-mediated reduction of PGG2 to PGH2 (peroxidase activity)

Oxygen addition to arachidonic acid (cyclooxygenase activity)

Cyclization and formation of PGH2

Functional Differences from COX-1

Normal Function in the Brain

Cellular Expression Pattern

In the normal brain, COX-2 expression is relatively low but detectable in specific cell types and regions:

Neurons: Moderate expression in hippocampal CA1 pyramidal neurons, cortical layer 2-4 neurons, and certain hypothalamic nuclei. Neuronal COX-2 is involved in synaptic plasticity, memory formation, and neuroprotection.

Endothelial cells: Low-level expression in cerebral blood vessels, contributing to vascular homeostasis and blood-brain barrier function.

Astrocytes: Constitutive expression at low levels, increasing dramatically during inflammation.

Microglia: Minimal expression in resting microglia; strongly upregulated upon activation.

Physiological Roles

COX-2-derived prostaglandins participate in:

Synaptic plasticity: PGE2 and PGD2 modulate long-term potentiation (LTP) and memory consolidation

Neuroprotection: Basal prostaglandin production maintains neuronal health

Cerebral blood flow: PGI2 and PGE2 regulate cerebrovascular tone

Thermoregulation: PGE2 acts on the hypothalamus to control body temperature

Sleep-wake cycles: Prostaglandin D2 (PGD2) is a key endogenous sleep inducer

Arachidonic Acid Cascade

Mermaid diagram (expand to render)

Role in Alzheimer's Disease

Evidence for COX-2 Involvement

COX-2 expression is significantly elevated in AD brain tissue, particularly in:

Neurons surrounding amyloid-beta (Aβ) plaques
Microglia associated with plaques
Endothelial cells in cerebral vasculature

Multiple studies have demonstrated:

2- to 10-fold increase in COX-2 immunoreactivity in AD hippocampus and cortex
Correlation between COX-2 levels and disease severity
Upregulation driven by Aβ through NF-κB and MAPK pathways [@wang2020]

Mechanisms of Contribution

COX-2 contributes to AD pathogenesis through multiple mechanisms:

Pro-inflammatory prostaglandin production: Elevated PGE2 levels drive chronic neuroinflammation, microglial activation, and cytokine release (IL-1β, IL-6, TNF-α).

Neuronal dysfunction: PGE2 directly interferes with synaptic plasticity and LTP, impairing memory formation.

Amyloidogenesis: Prostaglandins can increase amyloid precursor protein (APP) processing and Aβ production through NF-κB-mediated BACE1 upregulation.

Tau pathology: COX-2-derived inflammation promotes tau phosphorylation through activation of GSK-3β and CDK5. [@ayuso2024]

Blood-brain barrier disruption: PGE2 increases BBB permeability, facilitating peripheral immune cell infiltration.

Genetic Associations

PTGS2 polymorphisms have been linked to AD risk:

-765G>C promoter variant: Associated with reduced COX-2 expression and decreased AD risk
RS20417 variant: Conflicting reports on association with AD susceptibility
Gene-gene interactions with APOE4 may modify risk

Therapeutic Implications

The role of COX-2 in AD has driven extensive research into NSAID therapy:

Observational studies show reduced AD risk with chronic NSAID use
Clinical trials of selective COX-2 inhibitors (rofecoxib, celecoxib) showed mixed results
Timing of intervention may be critical - early intervention more effective
Failure of trials attributed to: inadequate dose, wrong timing, cardiovascular toxicity

Role in Parkinson's Disease

Evidence for COX-2 Involvement

COX-2 is upregulated in the substantia nigra pars compacta (SNc) of PD patients:

3- to 5-fold increase in COX-2 immunoreactivity in dopaminergic neurons
Correlation with disease duration and severity
Elevated PGE2 levels in cerebrospinal fluid

Mechanisms of Contribution

Dopaminergic neuron vulnerability: PGE2 promotes:

Oxidative stress through increased ROS production
Mitochondrial dysfunction
Apoptotic signaling pathways

Microglial activation: COX-2-derived prostaglandins activate microglia in the SNc, creating a neurotoxic microenvironment.

α-Synuclein pathology: Inflammation may accelerate α-synuclein aggregation and spread.

Mitochondrial complex I inhibition: MPP+ and 6-OHDA models show COX-2 contributes to complex I dysfunction. [@teismann2003]

Experimental Models

MPTP model: COX-2 knockout mice show reduced dopaminergic neuron loss
6-OHDA model: COX-2 inhibition provides neuroprotection
α-Synuclein models: COX-2 deletion reduces pathology and behavioral deficits

Therapeutic Implications

COX-2 inhibition in PD:

Neuroprotective effects in multiple preclinical models
Challenges: cardiovascular side effects, optimal timing
Novel approaches: brain-penetrant selective inhibitors, dual COX/LOX inhibitors

Role in Amyotrophic Lateral Sclerosis

Evidence for COX-2 Involvement

COX-2 is dramatically upregulated in ALS:

10- to 50-fold increase in spinal cord and motor cortex
Primarily expressed in activated microglia and astrocytes
PGE2 levels elevated in CSF and affected tissues

Mechanisms of Contribution

Motor neuron toxicity: PGE2 directly promotes:

Excitotoxicity through glutamate receptor modulation
Oxidative stress
Apoptotic pathways

Glial-mediated inflammation: Activated glial cells produce neurotoxic prostaglandins that accelerate motor neuron death.

Disease progression: PGE2 levels correlate with disease progression rate.

Clinical Implications

COX-2 inhibitors have been tested in ALS clinical trials
Challenges: timing of intervention, safety concerns
Current approaches: gene therapy targeting PGE2 receptors, microglial-specific inhibition

Therapeutic Targeting

Drug Development History

Novel Therapeutic Strategies

Brain-penetrant inhibitors: Development of COX-2 inhibitors that cross the BBB

Dimethylamino-celecoxib (DMC): Exhibits neuroprotective properties

Dual COX-2/LOX inhibitors: Reduce prostaglandin and leukotriene production

Licofelone: In clinical trials for neurodegenerative diseases

PGE2 receptor antagonists: Target downstream signaling

EP2 antagonists: Reduce neuroinflammation
EP4 antagonists: Modify disease progression

Gene therapy: Modulate PTGS2 expression using viral vectors

Natural compounds: Flavonoids and polyphenols with COX-2 modulatory activity

Challenges in Drug Development

Cardiovascular toxicity: Selective COX-2 inhibitors associated with increased MI/stroke risk
Timing of intervention: Late-stage intervention unlikely to be effective
Species differences: Rodent and human COX-2 pharmacology differ significantly
BBB penetration: Many compounds fail to reach therapeutic concentrations in brain
Biomarker development: Need for patient selection and treatment monitoring

Molecular Signaling Pathways

COX-2-Derived Prostaglandin Signaling

Mermaid diagram (expand to render)

Cross-talk with Other Inflammatory Pathways

NF-κB activation: Creates positive feedback loop with COX-2

NLRP3 inflammasome: PGE2 potentiates inflammasome activation

MAPK pathways: Bidirectional cross-talk modulates cell death/survival

Complement system: C5a receptor signaling intersects with PGE2 effects

Biomarker Potential

Fluid Biomarkers

CSF PGE2: Elevated in AD, PD, ALS; correlates with disease severity
CSF COX-2 activity: Potential marker for neuroinflammation
Plasma prostaglandin metabolites: Less specific but more accessible

Imaging Biomarkers

PET ligands: COX-2-targeted radiotracers in development
TSPO PET: Indirect marker of microglial activation reflecting COX-2 activity

Genetic Biomarkers

PTGS2 promoter polymorphisms may influence:
Disease risk
Treatment response
Age of onset

Research Timeline

Key Publications

[Smith WL, et al. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000](https://pubmed.ncbi.nlm.nih.gov/10966456/)

[Minghetti L. Cyclooxygenase-2 in neurodegenerative disease. J Neuropathol Exp Neurol. 2000](https://pubmed.ncbi.nlm.nih.gov/10989591/)

[Wang Q, et al. COX-2 in Alzheimer's disease. J Neurosci Res. 2020](https://pubmed.ncbi.nlm.nih.gov/32845543/)

[Teismann P, et al. COX-2 in Parkinson's disease. Exp Neurol. 2003](https://pubmed.ncbi.nlm.nih.gov/14637110/)

[McIlroy G, et al. COX-2 and prostaglandins in ALS. Nat Rev Neurol. 2020](https://pubmed.ncbi.nlm.nih.gov/32157299/)

[Choi SH, et al. COX-2 in neuroinflammation. Neuropharmacology. 2020](https://pubmed.ncbi.nlm.nih.gov/32818524/)

[Yang Y, et al. COX-2 and neuroinflammation in Alzheimer's disease. Front Aging Neurosci. 2023](https://pubmed.ncbi.nlm.nih.gov/37261239/)

[Ayuso-Blanco S, et al. COX-2 in tau pathology. Acta Neuropathol Commun. 2024](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Chen X, et al. Prostaglandin E2 receptors in neurodegeneration. Prog Lipid Res. 2024](https://pubmed.ncbi.nlm.nih/38242345/)

[Liu J, et al. Targeting COX-2 for Alzheimer's disease therapy. J Med Chem. 2024](https://pubmed.ncbi.nlm.nih.gov/38567512/)

Animal Models

Genetic Models

COX-2 knockout mice: Viable but with reduced inflammatory responses
Neuron-specific COX-2 transgenic: Show enhanced neuroinflammation
Humanized COX-2 knock-in: Improved translation to human disease

Disease Models

APP/PS1 mice: COX-2 deletion reduces Aβ pathology
MPTP model: COX-2 inhibition protects dopaminergic neurons
SOD1 model: COX-2 contributes to microglial activation and disease progression

Conclusions

The PTGS2 gene encodes COX-2, a pivotal enzyme linking neuroinflammation to neurodegenerative disease progression. While elevated COX-2 expression and prostaglandin production clearly contribute to disease pathogenesis through multiple mechanisms, therapeutic translation has proven challenging. The failure of selective COX-2 inhibitors in clinical trials for AD and PD highlights the complexity of targeting this pathway. Future directions include:

Timing-appropriate intervention: Early intervention before irreversible neuronal loss

Novel drug delivery: Brain-penetrant compounds and targeted delivery systems

Combination therapy: Dual targeting of COX-2 and related pathways

Biomarker-driven patient selection: Identifying patients most likely to benefit

Understanding neuroprotective roles: Exploiting the protective functions of certain prostaglandins

Understanding the cell-type-specific functions of COX-2 and developing tools to modulate them selectively remains a key challenge and opportunity for neurodegenerative disease therapy.

Comparative Analysis

COX-1 vs. COX-2

PTGS2 in Other Neurological Diseases

Beyond AD, PD, and ALS, COX-2 is implicated in:

Multiple sclerosis: Demyelination and lesion formation

Huntington's disease: Mutant huntingtin-induced inflammation

Frontotemporal dementia: Neuroinflammation contribution

Amyotrophic lateral sclerosis: Motor neuron vulnerability

Stroke and traumatic brain injury: Post-injury inflammation

Clinical Trial Considerations

Lessons learned from past trials:

Timing matters: Early intervention essential
Patient selection: Biomarker-driven enrollment
Endpoint selection: Sensitive clinical measures
Safety monitoring: Cardiovascular risk assessment
Dose optimization: Balancing efficacy and safety

Therapeutic Pipeline

Emerging Targets

New approaches under investigation:

EP receptor antagonists: Downstream prostaglandin targets

mPGES-1 inhibitors: Upstream PGE2 reduction

Dual COX/LOX inhibitors: Broader eicosanoid modulation

NO-releasing NSAIDs: Improved safety profile

Natural product derivatives: Plant-based compounds

Personalized Medicine

Future directions for COX-2 targeting:

Genetic profiling: PTGS2 variant analysis
Expression markers: Tissue COX-2 levels
Biomarker panels: Multi-analyte approaches
Combination biomarkers: Patient stratification

Pathway Diagram

The following diagram shows the key molecular relationships involving PTGS2 - Prostaglandin-Endoperoxide Synthase 2 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

PTGS2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ptgs2
kg_node_id	PTGS2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e2adc4dafa0d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ptgs2'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

325

Outgoing

360

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PTGS2 - Prostaglandin-Endoperoxide Synthase 2

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Introduction

Gene Overview

Gene Structure and Regulation

Genomic Architecture

Transcriptional Regulation

Post-Transcriptional Regulation

Protein Structure and Function

Structural Architecture

Key Structural Features

Catalytic Mechanism

Functional Differences from COX-1

Normal Function in the Brain

Cellular Expression Pattern

Physiological Roles

Arachidonic Acid Cascade

Role in Alzheimer's Disease

Evidence for COX-2 Involvement

Mechanisms of Contribution

Genetic Associations

Therapeutic Implications

Role in Parkinson's Disease

Evidence for COX-2 Involvement

Mechanisms of Contribution

Experimental Models

Therapeutic Implications

Role in Amyotrophic Lateral Sclerosis

Evidence for COX-2 Involvement

Mechanisms of Contribution

Clinical Implications

Therapeutic Targeting

Drug Development History

Novel Therapeutic Strategies

Challenges in Drug Development

Molecular Signaling Pathways

COX-2-Derived Prostaglandin Signaling

Cross-talk with Other Inflammatory Pathways

Biomarker Potential

Fluid Biomarkers

Imaging Biomarkers

Genetic Biomarkers

Research Timeline

Key Publications

Animal Models

Genetic Models

Disease Models

Conclusions

Comparative Analysis

COX-1 vs. COX-2

PTGS2 in Other Neurological Diseases

Clinical Trial Considerations

Therapeutic Pipeline

Emerging Targets

Personalized Medicine

See Also

Pathway Diagram

💬 Discussion